常山药业
(300255)
| 流通市值：88.84亿 | | | 总市值：89.15亿 |
| 流通股本：9.16亿 | | | 总股本：9.19亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,139,615,425.99 | 820,374,969.65 | 501,924,319.12 | 2,336,229,838.79 |
| 营业收入 | 1,139,615,425.99 | 820,374,969.65 | 501,924,319.12 | 2,336,229,838.79 |
| 二、营业总成本 | 1,439,650,840.38 | 946,281,789.41 | 507,965,611.18 | 2,306,465,630.59 |
| 营业成本 | 784,467,890.22 | 507,703,256.44 | 302,807,779.13 | 1,298,450,320.44 |
| 税金及附加 | 17,339,727.38 | 13,289,900.84 | 9,072,294.39 | 22,022,950 |
| 销售费用 | 348,418,548.74 | 233,577,082.61 | 96,077,843.47 | 613,599,991.9 |
| 管理费用 | 112,623,023.81 | 75,170,333.03 | 36,126,738.93 | 133,132,321.85 |
| 研发费用 | 100,561,746.37 | 70,070,734.81 | 38,452,690.19 | 145,014,172.59 |
| 财务费用 | 76,239,903.86 | 46,470,481.68 | 25,428,265.07 | 94,245,873.81 |
| 其中:利息费用 | 77,386,645.94 | 48,707,093.22 | 23,101,719.26 | 93,043,168.59 |
| 其中:利息收入 | 1,418,143.65 | 1,154,309.82 | 617,663.84 | 1,993,819.67 |
| 资产处置收益 | - | - | - | -13,291.69 |
| 资产减值损失(新) | -121,354,856.55 | -51,316,610.91 | - | -11,555,265.26 |
| 信用减值损失(新) | 422,670.77 | 1,237,000.43 | 1,598,914.09 | -9,417,816.17 |
| 其他收益 | 14,689,581.79 | 12,874,484.07 | 10,195,046.16 | 11,674,706.44 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -406,278,018.38 | -163,111,946.17 | 5,752,668.19 | 20,452,541.52 |
| 加:营业外收入 | 131,700.64 | 47,443.05 | 9,309.05 | 213,953.21 |
| 减:营业外支出 | 781,984.93 | 276,471.03 | 17,808 | 2,550,189.08 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -406,928,302.67 | -163,340,974.15 | 5,744,169.24 | 18,116,305.65 |
| 减:所得税费用 | -11,988,189.41 | -2,148,047.88 | 5,185,487.4 | 7,960,208.17 |
| 六、净利润 | -394,940,113.26 | -161,192,926.27 | 558,681.84 | 10,156,097.48 |
| 持续经营净利润 | -394,940,113.26 | -161,192,926.27 | 558,681.84 | 10,156,097.48 |
| 归属于母公司股东的净利润 | -388,330,627.87 | -155,878,327.3 | 4,541,481.07 | 17,513,464.49 |
| 少数股东损益 | -6,609,485.39 | -5,314,598.97 | -3,982,799.23 | -7,357,367.01 |
| (一)基本每股收益 | -0.42 | -0.17 | 0 | 0.02 |
| (二)稀释每股收益 | -0.42 | -0.17 | 0 | 0.02 |
| 八、其他综合收益 | -928,525.69 | -874,455.63 | -680,353.64 | -4,356,299.18 |
| 归属于母公司股东的其他综合收益 | -928,525.69 | -874,455.63 | -680,353.64 | -4,356,299.18 |
| 九、综合收益总额 | -395,868,638.95 | -162,067,381.9 | -121,671.8 | 5,799,798.3 |
| 归属于母公司股东的综合收益总额 | -389,259,153.56 | -156,752,782.93 | 3,861,127.43 | 13,157,165.31 |
| 归属于少数股东的综合收益总额 | -6,609,485.39 | -5,314,598.97 | -3,982,799.23 | -7,357,367.01 |
| 公告日期 | 2023-10-25 | 2023-08-31 | 2023-04-27 | 2023-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |